The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin

Nicole M Gerlanc,1 Jennifer Cai,2 Joseph Tkacz,1 Susan C Bolge,2 Brenna L Brady1 1Health Analytics, LLC Columbia, MD, USA; 2Janssen Scientific Affairs, LLC Titusville, NJ, USA Objective: Type 2 diabetes mellitus (T2DM) is a chronic condition complicated by being overweight or obese. This study used...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gerlanc NM, Cai J, Tkacz J, Bolge SC, Brady BL
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://doaj.org/article/43fc34719f7245eb8bfe5006f4af0d0b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:43fc34719f7245eb8bfe5006f4af0d0b
record_format dspace
spelling oai:doaj.org-article:43fc34719f7245eb8bfe5006f4af0d0b2021-12-02T07:54:28ZThe association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin1178-7007https://doaj.org/article/43fc34719f7245eb8bfe5006f4af0d0b2017-03-01T00:00:00Zhttps://www.dovepress.com/the-association-of-weight-loss-with-patient-experience-and-outcomes-in-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Nicole M Gerlanc,1 Jennifer Cai,2 Joseph Tkacz,1 Susan C Bolge,2 Brenna L Brady1 1Health Analytics, LLC Columbia, MD, USA; 2Janssen Scientific Affairs, LLC Titusville, NJ, USA Objective: Type 2 diabetes mellitus (T2DM) is a chronic condition complicated by being overweight or obese. This study used a patient survey to assess health, satisfaction, and diabetes self-management in relation to weight management.Methods: A survey including the Current Health Satisfaction Questionnaire, Diabetes Distress Scale, and Diabetes Treatment Satisfaction Questionnaire was administered using an online platform to a sample of 205 patients with T2DM prescribed canagliflozin. Patients were placed into 5 groups based on their self-reported weight change since initiation of canagliflozin: Lost >10 lbs, Lost 5–10 lbs, Lost <5 lbs, No Change, and Gained Weight. One-way ANOVAs, Kruskall–Wallis tests, and multivariable regression were used to explore differences between weight loss groups. Results: The majority of patients (66.8%) reported losing weight. Compared to other groups, patients who lost >10 lbs were more likely to be engaged in a weight loss program for at least 6 months. Patients in the Lost >10 lbs and Lost 5–10 lbs groups reported the greatest satisfaction with canagliflozin (p<0.05 for both). Multivariable analyses controlling for patient demographic and treatment characteristics revealed that losing >10 lbs was associated with reduced diabetes distress, improved A1c and blood glucose levels, and decreased perceived frequency of hyperglycemia (p<0.05).Conclusion: Increased positive patient outcomes, engagement in diabetes self-management, and medication satisfaction were observed among patients who reported weight loss. These findings suggest that a T2DM regimen that includes canagliflozin as part of a weight loss regimen can help improve patient outcomes and experiences with T2DM. Keywords: T2DM, patient outcomes, diabetes self-management, SGLT2 inhibitor, weight managementGerlanc NMCai JTkacz JBolge SCBrady BLDove Medical PressarticleDiabetesSurveyPatient ExperienceSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 10, Pp 89-99 (2017)
institution DOAJ
collection DOAJ
language EN
topic Diabetes
Survey
Patient Experience
Specialties of internal medicine
RC581-951
spellingShingle Diabetes
Survey
Patient Experience
Specialties of internal medicine
RC581-951
Gerlanc NM
Cai J
Tkacz J
Bolge SC
Brady BL
The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin
description Nicole M Gerlanc,1 Jennifer Cai,2 Joseph Tkacz,1 Susan C Bolge,2 Brenna L Brady1 1Health Analytics, LLC Columbia, MD, USA; 2Janssen Scientific Affairs, LLC Titusville, NJ, USA Objective: Type 2 diabetes mellitus (T2DM) is a chronic condition complicated by being overweight or obese. This study used a patient survey to assess health, satisfaction, and diabetes self-management in relation to weight management.Methods: A survey including the Current Health Satisfaction Questionnaire, Diabetes Distress Scale, and Diabetes Treatment Satisfaction Questionnaire was administered using an online platform to a sample of 205 patients with T2DM prescribed canagliflozin. Patients were placed into 5 groups based on their self-reported weight change since initiation of canagliflozin: Lost >10 lbs, Lost 5–10 lbs, Lost <5 lbs, No Change, and Gained Weight. One-way ANOVAs, Kruskall–Wallis tests, and multivariable regression were used to explore differences between weight loss groups. Results: The majority of patients (66.8%) reported losing weight. Compared to other groups, patients who lost >10 lbs were more likely to be engaged in a weight loss program for at least 6 months. Patients in the Lost >10 lbs and Lost 5–10 lbs groups reported the greatest satisfaction with canagliflozin (p<0.05 for both). Multivariable analyses controlling for patient demographic and treatment characteristics revealed that losing >10 lbs was associated with reduced diabetes distress, improved A1c and blood glucose levels, and decreased perceived frequency of hyperglycemia (p<0.05).Conclusion: Increased positive patient outcomes, engagement in diabetes self-management, and medication satisfaction were observed among patients who reported weight loss. These findings suggest that a T2DM regimen that includes canagliflozin as part of a weight loss regimen can help improve patient outcomes and experiences with T2DM. Keywords: T2DM, patient outcomes, diabetes self-management, SGLT2 inhibitor, weight management
format article
author Gerlanc NM
Cai J
Tkacz J
Bolge SC
Brady BL
author_facet Gerlanc NM
Cai J
Tkacz J
Bolge SC
Brady BL
author_sort Gerlanc NM
title The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin
title_short The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin
title_full The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin
title_fullStr The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin
title_full_unstemmed The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin
title_sort association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin
publisher Dove Medical Press
publishDate 2017
url https://doaj.org/article/43fc34719f7245eb8bfe5006f4af0d0b
work_keys_str_mv AT gerlancnm theassociationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin
AT caij theassociationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin
AT tkaczj theassociationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin
AT bolgesc theassociationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin
AT bradybl theassociationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin
AT gerlancnm associationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin
AT caij associationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin
AT tkaczj associationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin
AT bolgesc associationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin
AT bradybl associationofweightlosswithpatientexperienceandoutcomesinapopulationofpatientswithtype2diabetesmellitusprescribedcanagliflozin
_version_ 1718399098639351808